A preclinical study on the efficacy and safety of a new vaccine against Coxsackievirus B1 reveals no risk for accelerated diabetes development in mouse models
Pär Larsson(Swedish Defence Research Agency), Malin Flodström‐Tullberg(Karolinska University Hospital), Renata Utorova(Karolinska University Hospital), Pascal Chaux(Sanofi (France)), S. Jacobson(Karolinska University Hospital), Tadepally Lakshmikanth(Hammersmith Hospital), Erna Domsgen(Karolinska University Hospital), Mikael Knip(Åbo Akademi University), Valérie Lecouturier(Sanofi (France)), Maarit Oikarinen(Tampere University), Jeffrey W. Almond(Sanofi (France)), Nicolas Devard(Sanofi (France)), Olli H. Laitinen(Tampere University of Applied Sciences), Minni R. L. Koivunen, Heikki Hyöty(Tampere University of Applied Sciences)
Cited by 43
Related Papers
The Dynamics of the Human Infant Gut Microbiome in Development and in Progression toward Type 1 Diabetes
|Cell Host & Microbe|2015|1.2k
Natural history of the infant gut microbiome and impact of antibiotic treatment on bacterial strain diversity and stability
|Science Translational Medicine|2016|1.1k